Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Nov 20, 2025
Reporting period
Not applicable
Filed with the SEC
Nov 24, 2025
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0000943819-25-000170
Filed / recorded
Nov 24, 2025, 8:42 PM UTC
Added to OQRO
Oct 2, 2026, 12:28 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
RESMED INC
Issuer CIK
943819
Ticker
RMD
Reporting person
Michael J. Farrell
Relationship
Director, Officer
Officer title
Chairman and CEO
Security
ResMed Common Stock
Table
Non-derivative (Table I)
Transaction date
Nov 20, 2025
Transaction code
A
Shares / units
13,551
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
473,520
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on November 20, 2025, when the compensation and leadership development committee certified that the performance metrics were met.